ライフサイエンスコーパス: HIPEC

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します

1 HIPEC through the closed abdomen technique employed cisp

2 disruptions associated with intra-abdominal HIPEC is critical to ensure effective anesthetic managem

3 are at risk for poor clinical outcomes after HIPEC + CS, including greater risk of 30-day morbidity a

4 uvant chemotherapy in the setting of CRS and HIPEC for PMs.

5 CRS and HIPEC to treat PSM has a steep learning curve requiring

6 CRS and HIPEC to treat PSM is a complex procedure with a signifi

7 to be associated with survival after CRS and HIPEC, but no definitive analysis has been made to valid

8 on to a curative procedure combining CRS and HIPEC.

9 ry to ensure surgical proficiency in CRS and HIPEC.

10 variables on overall survival after CRS and HIPEC.

11 ere enrolled to undergo laparoscopic CRS and HIPEC.

12 variables on overall survival after CRS and HIPEC.

13 m colorectal cancer are treated with CRS and HIPEC.

14 en patients had a complete cytoreduction and HIPEC, 10 (77%) laparoscopically and 3 (23%) were conver

15 lity and safety of cytoreductive surgery and HIPEC via the laparoscopic route in selected patients wi

16 d hyperthermic intraperitoneal chemotherapy (HIPEC) achieve good results in selected patients with pe

17 Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery have been shown to bene

18 d hyperthermic intraperitoneal chemotherapy (HIPEC) are being widely used in the treatment of patient

19 d hyperthermic intraperitoneal chemotherapy (HIPEC) consolidated through an international registry st

20 h hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal cancers can be associated with sig

21 h hyperthermic intraperitoneal chemotherapy (HIPEC) has become an important therapeutic option for se

22 f hyperthermic intraperitoneal chemotherapy (HIPEC) is to eradicate microscopic residual tumor after

23 n hyperthermic intraperitoneal chemotherapy (HIPEC)-like treated 3D colorectal tumor mimics.

24 d hyperthermic intraperitoneal chemotherapy (HIPEC).

25 itigate morbidity in patients undergoing CRS/HIPEC.

26 erative morbidity in patients undergoing CRS/HIPEC.

27 ion and morbidity in patients undergoing CRS/HIPEC.

28 cells and nontransformed human enterocytes (HIPEC) were subjected to 10% average cyclic strain at 10

29 ion of DDC improves the efficacy of existing HIPEC protocols in a safe way and may open the door to a

30 Ninety-eight patients scheduled for HIPEC + CS completed the Center for Epidemiologic Studie

31 pen the door to a more effective, multimodal HIPEC.

32 inment of the perioperative complications of HIPEC.

33 Anesthetic management of HIPEC is further impacted by these developments.

34 Available data investigating the outcomes of HIPEC are mostly limited to single-center studies.

35 investigating the postoperative outcomes of HIPEC.

36 A retrospective review of HIPEC cases performed for primary and metastatic periton

37 ity Improvement Program hospitals performing HIPEC have acceptable rates of morbidity and mortality.

38 Open high-pressure HIPEC with oxaliplatin is feasible in the pig.

39 eal chemotherapy with cytoreductive surgery (HIPEC + CS).

40 tion to the ambitious, long-lasting surgery, HIPEC causes significant fluid, blood and protein losses

41 nsive care management of patients undergoing HIPEC.

42 tion [CCR], 2 or 3; P < .001), and not using HIPEC (P = .030) as independent predictors for a poorer

43 treated by 131 procedures combining CRS with HIPEC.

44 Cytoreducion with HIPEC is an effective but potentially morbid treatment o

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。